Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label combination trial of BI 765063 + ezabenlimab with or without BI 836880, chemotherapy, or cetuximab in HNSCC or HCC
jRCT2031210650Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Randomised, open-label trial of BI 765063, ezabenlimab, BI 836880, cetuximab, paclitaxel and 4 more in head and neck squamous cell carcinoma (HNSCC) and hepatocellular carcinoma (HCC) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Objective response rate (ORR). Started Feb 2022; status: active, not recruiting.
02
Drugs
BI 765063ezabenlimabBI 836880cetuximabpaclitaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2031210650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210650.